AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03715465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 0.5 MG
Description: Melatonin tablet
Study NCT03715465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 MG
Description: Melatonin tablet
Study NCT03715465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dim Light Melatonin Onset (salivary)
Description: Test to determine the time of melatonin onset in saliva under dim light conditions
Study NCT01958567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Study NCT04392414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent hyperimmune plasma
Description: Subjects to receive double convalescent hyperimmune plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
Study NCT04392414 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-convalescent fresh frozen plasma (Standard plasma)
Description: Subjects to receive double standard plasma units of 300 ml each, with the 2nd unit administered no later than 24 hrs after the first one
Study NCT02665689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
Study NCT02665689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
Study NCT00904124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
Study NCT00904124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: cellulose, alginate, guar gum
Description: 6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
Study NCT05452382 — intervention group
Intervention type: PROCEDURE
Intervention: Partial colecctomy
Description: Segmental resection of appendiceal adenocarcinoma including terminal ileum and cecum
Study NCT05452382 — intervention group
Intervention type: PROCEDURE
Intervention: Hemicolectomy
Description: Formal right hemicolectomy including terminal ileum, cecum, and ascending colon
Study NCT03352440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy - Kinect
Description: Group with Cerebral Palsy that will perform the task on Kinect
Study NCT03352440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy - Touchscreen
Description: Group with Cerebral Palsy that will perform the task on Touchscreen
Study NCT03352440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Kinect
Description: Group with typical development that will perform the task on Kinect
Study NCT03352440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group - Touchscreen
Description: Group with typical development that will perform the task on Touchscreen
Study NCT00775567 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose powder
Description: 30g in 250ml water twice a day
Study NCT06488196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing (MI) is a person-centered, goal-oriented psychotherapeutic intervention designed to enhance the recipient's motivation for and commitment to a target behavior or behavior change. MI's core action mechanisms include strengthening the recipient's change talk (e.g., assertions about desire and commitment toward the target behavior) and softening the recipient's sustain talk (e.g., statements about barriers). MI clinicians achieve these goals using specific micro-skills (e.g., reflective listening) that reflect MI's fundamental spirits (i.e. collaboration, acceptance, compassion, evocation.
Study NCT06488196 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: TAU included the opportunity for mothers to meet with a NICU psychologist or psychology trainee at least once-per-week for supportive care.
Study NCT03057444 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SymbioIntest
Description: The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
Study NCT01320228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Alli treatment plus placebo (rice flour)
Study NCT01320228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capolac
Description: Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
Study NCT01320228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax fiber
Description: Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
Study NCT01320228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capolac+Flax fiber
Description: Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
Study NCT01295333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation
Study NCT01295333 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: The initiation of LT4 as soon as the first biological signs of hypothyroidism.
Study NCT00284115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait trainer
Description: Mechanical gait repetitive training
Study NCT00284115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Physiotherapeutic conventional rehabilitation
Study NCT04331899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Lambda-1a
Description: Peginterferon Lambda-1a (180 ug subcutaneous injection) single dose along with Standard of Care
Study NCT04331899 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection along with Standard of Care Treatment for COVID-19 Infection
Study NCT04427085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound assessment of optic nerve sheath diameter
Description: Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
Study NCT04427085 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of optic nerve sheath diameter
Description: Using ultrasonography, optic nerve sheath diameter is measured during perioperative period.
Study NCT04721873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate
Description: Patients will be randomized to either once-daily, oral phentermine-topiramate 15-92mg or placebo, in a 1:1 fashion, for 22 weeks, with clinic visits with an obesity medicine specialist, for intensive counseling for diet and lifestyle intervention. All patients will be dose-titrated within the first 4 weeks, starting at phentermine-topiramate 3.75-23mg, or placebo. Dose titration will be performed as follows 3.75-23mg x 1 week --> 7.5-46mg x 1 week --> 11.25-69mg x 1 week --> 15-92mg. Patients who experience side effects would undergo slower titration, and dose would be down-titrated and capped at highest tolerated dose.
Study NCT04721873 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, titrated as active intervention
Study NCT03068962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot Juice
Description: Beetroot Juice
Study NCT03068962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buxton water
Description: natural mineral water
Study NCT03068962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antiseptic mouthwash then beetroot juice
Description: Chlorhexidine glocunate
Study NCT04704180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitation Tuchking Position
Description: The nurse placed the neonate in the facilitated tucking position by rolling up a sizeable sterile towel in a U-shape and covering it with covers available in the unit and then placed the neonate in a supine position. The physiological parameters at admission and in the 15th and 30th minutes of facilitated tucking were recorded. In the 30th minute of facilitated tucking, the researcher and the observer nurse completed the COMFORTneo simultaneously but separately. The neonate was in the facilitated tucking position until delivered to its mother. The researcher and the observer nurse had a full view of the neonate's face and body when completing the COMFORTneo, which took them about two minutes. After the neonate stabilized (within the first half an hour to an hour), it was delivered to its mother for breastfeeding based on specialist consent. The first breastfeeding was performed and completed the LATCH by researcher and the observer nurse.
Study NCT01154413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive education of the doctor/nursing team on the protocol
Study NCT01154413 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Intensive education of the doctor/nursing team on the protocol
Study NCT02811705 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Quality of life
Study NCT00996840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 3mg
Description: 3 mg SB-681323 Intravenous administration infused over 4 hours
Study NCT00996840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 7.5 mg
Description: 7.5 mg SB-681323 Intravenous administration infused over 24 hours
Study NCT00996840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 7.5mg
Description: 7.5 mg SB-681323 Intravenous administration infused over 4 hours
Study NCT00996840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-681323 Intravenous 10mg
Description: 10 mg SB-681323 Intravenous administration infused over 24 hours
Study NCT00996840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match intervention
Study NCT02795988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMU-131
Description: IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
Study NCT02795988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
Description: Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
Study NCT02494141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Dietary Supplement
Study NCT02494141 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00942409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
Study NCT00001703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: von Hippel-Lindau peptide vaccine
Description: 1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
Study NCT00485394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-551
Description: OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
Study NCT00485394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-551
Description: OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
Study NCT00485394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle placebo
Description: OT-551 0% ophthalmic solution, 2 drops 4 times daily
Study NCT03167515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 074-6751 Lotion
Description: Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
Study NCT02269657 — intervention group
Intervention type: DEVICE
Intervention: EOS® imaging system
Description: The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
Study NCT01273350 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Carotid PTA and stenting
Description: Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
Study NCT03475303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early hospital discharge
Description: early hospital discharge at 8-12 hours for women undergone elective cesarean section
Study NCT06308861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Amg dose Group
Description: Orally, Amg tablet single administration
Study NCT04027621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
Study NCT04027621 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule and Fiber Sachet
Description: A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic capsule and Fiber Sachet
Description: A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic capsule and Placebo sachet
Description: A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic capsule and Placebo sachet
Description: A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule and Fiber Sachet
Description: A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Fiber Sachet
Description: A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT02445560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo capsule and Placebo sachet
Description: A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein.
Study NCT01279200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Midcycle ultrasound + hCG injection
Description: Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
Study NCT01279200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urinary LH kits
Description: Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
Study NCT05179512 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium dispensing claim is used as the reference group.
Study NCT05179512 — intervention group
Intervention type: DRUG
Intervention: salmeterol-fluticasone
Description: Salmeterol/Fluticasone dispensing claim is used as the exposure group.
Study NCT04549389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity shockwave therapy
Description: LiST will be applied in the perineum of the patients by using Dornier Aries 2 shockwave machine (5000shockwaves per session, energy level 7)
Study NCT01949701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A*0201restricted URLC10 peptides with adjuvant
Description: Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A\*0201restricted URLC10 peptides with adjuvant.
Study NCT02667613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT-ILE
Description: Hand and arm bimanual intensive therapy including lower extremities
Study NCT02667613 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual customary care
Study NCT04615169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-component cognitive intervention with simulated everyday tasks (MCI-SET)
Description: 2 hours per session: consisted primarily of modified everyday cognitive tasks, which were adjusted for individuals and for the group by the group leader to provide an error-reduction learning environment. Each session consisted of: (1) Warm-up: a 15-30 minute dual task of motor-cognitive exercises that increase arousal level and provide cognitive stimulation. For example, at the beginning of the group, the members would sing a song, mimic dance movement of the group leader, and clap hands when specific words occur in the song.~(2) 30-minutes guided and repetitive practices of contextually-relevant simulated everyday cognitive tasks with one 15 to 20- minute break in between; Cognitive tasks addressed complex attention, visual scanning, auditory attention, visual and motor memory, auditory memory, prospective memory, executive functioning, problem solving, etc.